Study to Monitor Congestion in Adults with Chronic Heart Failure and Reduced Heart Pumping Function

What this Trial Is About

Chronic heart failure HF with reduced ventricular ejection fraction is a serious condition leading to high rates of death and hospitalization, particularly in older adults. Congestion is a key cause of symptoms and hospital stays in HF patients, and early signs of congestion in symptom-free patients can indicate risk for developing symptomatic HF. Researchers are studying various congestion markers, including clinical, biological, and ultrasound measures, to better predict outcomes such as death, hospitalizations, and intravenous diuretic treatments in patients with chronic HF and reduced ejection fraction. Participants in this study undergo a comprehensive evaluation during a scheduled day hospitalization or consultation. This includes a clinical examination focused on congestion using specific scoring systems, multiple Doppler ultrasounds of the heart, lungs, peritoneum, jugular vein, and kidneys, as well as liver elastography. Blood samples are collected for biological tests and biobanking. Some ultrasounds are optional. Participants complete quality of life questionnaires at discharge and at 3, 12, and 24 months. Telephone follow-ups also occur at these time points. Throughout the study, participants are monitored for outcomes such as all-cause death, hospitalizations for acute heart failure, and intravenous diuretics use over 24 months after their hospitalization or consultation. Additional assessments include blood tests for heart and kidney function and repeated quality of life measures. This approach aims to identify important congestion markers associated with worsening heart failure and related complications. The study lasts over two years with evaluations at multiple intervals to track participants health and quality of life.

CHF-COV Reduced (Chronic Heart Failure With Reduced Ejection Fraction - COngestion eValuation)